Federal contract award
75N93021C00041
INNOVATIVE PEDIATRIC ORAL FORMULATIONS FOR SECOND LINE TUBERCULOSIS DRUGS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | SMALL BUSINESS SET ASIDE - TOTAL |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $1.5M |
| Current contract value | $1.5M |
| Potential contract value / ceiling | $1.5M |
| Start date | Sep 3, 2021 |
| Current end date | May 31, 2025 |
| Potential end date | May 31, 2025 |
| Latest award activity | Mar 20, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Mar 20, 2025 | P00007 | $0 | PHS SBIR 2021-1 TOPIC 97 |
| Jan 6, 2025 | P00006 | $0 | PHS SBIR 2021-1 TOPIC 97 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.